Equity Profile

ARGX

argenx SE

Health CareBiotechnology$54.5B

Jul23Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

argenx SE is a biotechnology company focused on developing innovative therapies for severe autoimmune diseases and cancer. With a market cap of $54 billion, it operates in the health care sector, addressing significant unmet medical needs through its advanced drug development pipeline.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, reflecting how much profit is attributed to each share of stock.

$5.16

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations, especially in the competitive biotech industry.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.11%

Avg Stock Reaction

+0.79%

Last Quarter Recap

In Q1 2026, argenx reported an EPS of $5.52, exceeding expectations by 6.94%. However, the stock declined by 2.51% the following day, indicating mixed market reactions despite strong earnings.

Management Promises & Guidance

Continued focus on advancing clinical trials for its leading therapies.
Commitment to maintaining strong financial performance and shareholder value.
Plans to provide updates on pipeline progress in upcoming calls.

Expectations

Wall Street Expectations

Overall, analysts expect argenx to continue its trend of beating EPS estimates, given its strong track record. However, the market is cautious about revenue growth and future guidance.

Bull Case

If argenx delivers another strong EPS surprise and provides optimistic guidance on its pipeline, it could lead to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could trigger a sharp decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$5.16

EPS is a key indicator of the company's profitability and financial health, reflecting how much profit is attributed to each share of stock.

Revenue Growth

N/A

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations, especially in the competitive biotech industry.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2 2026?

Given the company's strong history of beating EPS estimates, this figure will be critical for investor confidence and stock performance.

What updates will be provided on the drug pipeline?

Investors will closely watch for any advancements or setbacks in clinical trials, as these can significantly impact future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating argenx's ability to deliver strong EPS growth due to its robust pipeline and recent clinical trial successes.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting strong operational performance.

Options pricing indicates a significant expected move, reflecting heightened investor interest and potential upside.

Recent historical patterns show that the stock tends to react positively to earnings beats.

Key Risk

If the EPS comes in below $5.16, it could undermine confidence in the company's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued strong earnings against concerns about future revenue growth and pipeline developments.

Bull Confirmed If

An EPS of $5.52 or higher would confirm the bullish outlook and likely lead to a positive stock reaction.

Bear Confirmed If

An EPS below $5.16 would reinforce bearish sentiment and could lead to a decline in the stock price.

Pre-Earnings Positioning

Options Market

Implied Move

±14.75%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.7% while ARGX has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

31.0%

Calls (2K)P/C Ratio: 0.03Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If argenx beats expectations, history suggests the stock could rise by around 0.79% on the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with history indicating an average drop of around 2.51% following disappointing earnings.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of ongoing clinical trials.
2Guidance on future revenue expectations.
3Details regarding any new partnerships or collaborations.
4Insights into market demand for their therapies.
5Management's outlook on competitive pressures in the biotech sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Domino's Pizza, Inc.

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, reflecting how much profit is attributed to each share of stock.

$5.16

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations, especially in the competitive biotech industry.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+253.11%

Avg Stock Reaction

+0.79%

Last Quarter Recap

In Q1 2026, argenx reported an EPS of $5.52, exceeding expectations by 6.94%. However, the stock declined by 2.51% the following day, indicating mixed market reactions despite strong earnings.

Management Promises & Guidance

Continued focus on advancing clinical trials for its leading therapies.
Commitment to maintaining strong financial performance and shareholder value.
Plans to provide updates on pipeline progress in upcoming calls.

Expectations

Wall Street Expectations

Overall, analysts expect argenx to continue its trend of beating EPS estimates, given its strong track record. However, the market is cautious about revenue growth and future guidance.

Bull Case

If argenx delivers another strong EPS surprise and provides optimistic guidance on its pipeline, it could lead to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could trigger a sharp decline in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$5.16

EPS is a key indicator of the company's profitability and financial health, reflecting how much profit is attributed to each share of stock.

Revenue Growth

N/A

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations, especially in the competitive biotech industry.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2 2026?

Given the company's strong history of beating EPS estimates, this figure will be critical for investor confidence and stock performance.

What updates will be provided on the drug pipeline?

Investors will closely watch for any advancements or setbacks in clinical trials, as these can significantly impact future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating argenx's ability to deliver strong EPS growth due to its robust pipeline and recent clinical trial successes.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting strong operational performance.

Options pricing indicates a significant expected move, reflecting heightened investor interest and potential upside.

Recent historical patterns show that the stock tends to react positively to earnings beats.

Key Risk

If the EPS comes in below $5.16, it could undermine confidence in the company's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued strong earnings against concerns about future revenue growth and pipeline developments.

Bull Confirmed If

An EPS of $5.52 or higher would confirm the bullish outlook and likely lead to a positive stock reaction.

Bear Confirmed If

An EPS below $5.16 would reinforce bearish sentiment and could lead to a decline in the stock price.

Pre-Earnings Positioning

Options Market

Implied Move

±14.75%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.7% while ARGX has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

31.0%

Calls (2K)P/C Ratio: 0.03Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If argenx beats expectations, history suggests the stock could rise by around 0.79% on the following day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with history indicating an average drop of around 2.51% following disappointing earnings.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of ongoing clinical trials.
2Guidance on future revenue expectations.
3Details regarding any new partnerships or collaborations.
4Insights into market demand for their therapies.
5Management's outlook on competitive pressures in the biotech sector.